Vanguard Personalized Indexing Management LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Vanguard Personalized Indexing Management LLC increased its holdings in Regeneron Pharmaceuticals by 7.9% in the second quarter, bringing its total to 10,853 shares valued at approximately $5.7 million.
• Regeneron Pharmaceuticals reported earnings per share of $12.89 for the last quarter, significantly beating analysts' expectations of $8.43, with a revenue of $3.68 billion.
• The company recently declared a quarterly dividend, equivalent to $0.88 per share, resulting in an annualized yield of 0.6%.

Vanguard Personalized Indexing Management LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 10,853 shares of the biopharmaceutical company's stock after acquiring an additional 792 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Regeneron Pharmaceuticals were worth $5,699,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. E Fund Management Hong Kong Co. Ltd. grew its position in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares during the period. Activest Wealth Management grew its position in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $27,000. Saudi Central Bank acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $27,000. Finally, Colonial Trust Advisors acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $32,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 1.2%

Shares of NASDAQ REGN opened at $557.73 on Tuesday. The stock has a market cap of $59.11 billion, a P/E ratio of 14.06, a PEG ratio of 1.80 and a beta of 0.31. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,024.36. The business's fifty day simple moving average is $573.67 and its 200-day simple moving average is $563.46.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period last year, the firm earned $11.56 earnings per share. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research reports. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Jefferies Financial Group upped their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research note on Wednesday, August 27th. Canaccord Genuity Group restated a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Citigroup upped their price target on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the stock a "buy" rating in a research note on Monday. Finally, Raymond James Financial upgraded Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $817.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.